News >

ODAC Supports Necitumumab for Squamous NSCLC

Silas Inman @silasinman
Published: Thursday, Jul 09, 2015

Dr. Richard Pazdur

Richard Pazdur, MD

The FDA’s Oncologic Drugs Advisory Committee (ODAC) supported the approval of necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer (NSCLC), according to an informal poll conducted by Richard Pazdur, MD, at an advisory meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x